¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Host Cell Factor C1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® muscle cell(=muscle fiber) ÇÑ±Û ±ÙÀ°¼¼Æ÷
¼³¸í   
  ±ÙÀ°Àº ¼öÀDZÙ(ÀǽĿ¡ ÀÇÇØ¼­ Á¶ÀýÀÌ °¡´ÉÇÑ ±ÙÀ°: ¿¹¸¦ µé¾î ´Ù¸®, ÆÈ, ¾ó±¼±ÙÀ° µî)°ú ºÒ¼öÀDZÙ(Àǽİú ¹«°üÇϰԠÁ¶ÀýÇÏÁö ¾Ê¾Æµµ ¿òÁ÷À̴ ±ÙÀ°: ¿¹¸¦ µé¾î ½ÉÀå±Ù, ¼ÒÈ­±â°ü¿¡ ºÐÆ÷Çϴ ±ÙÀ° µî)À¸·Î ³ª´©¾îÁö¸ç, ±ÙÀ°¼¼Æ÷ÀÇ ¸ð¾çÀº ´ÙÀ½°ú °°´Ù(¼öÀDZÙ, ºÒ¼öÀDZ٠¿Ü¿¡ ½ÉÀå¿¡ Àִ ½ÉÀå±ÙÀº ºÒ¼öÀDZٿ¡ ÇØ´çÇÏÁö¸¸ ±× ¸ð¾çÀº ¼öÀDZٰú °°¾Æ µû·Î ºÐ·ùÇÑ´Ù).
  
  ±ÙÀ°¼¼Æ÷
¿µ¹® white blood cell(WBC), leukocyte ÇÑ±Û ¹éÇ÷±¸
¼³¸í   
  Ç÷¾×³»¿¡ °ñ¼ö±¸°è¼¼Æ÷¿Í ¸²ÇÁ°è¼¼Æ÷, ´ÜÇÙ±¸°è¼¼Æ÷¸¦ ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ¹éÇ÷±¸ÀÇ Áõ°¡°¡ ÀÖÀ¸¸é ´ë°³ °¨¿°ÀÌ Àְųª, È¤Àº Å»¼öÇö»óÀÌ ÀÖÀ½À» ÀǹÌÇÑ´Ù. ¶ÇÇÑ Áö³ªÄ£ ¹éÇ÷±¸¼öÀÇ °¨¼Ò´Â ÀÎü³» ¸é¿ª±â´ÉÀÌ ¶³¾îÁ® ÀÖÀ½À» ÀǹÌÇϸç, ´Ù¸¥ Áúº´¿¡ ÀÇÇØ ³ªÅ¸³ª´Â ÀÌÂ÷ÀûÀΠÇö»óÀÌ ¾Æ´ÑÁö ²À Áø´ÜÀ» ¹Þ¾Æº¸¾Æ¾ß ÇÑ´Ù.
¿µ¹® mast cell ÇÑ±Û ºñ¸¸ ¼¼Æ÷
¼³¸í   
  µ¿¹°ÀÇ °áÇÕ Á¶Á÷ °¡¿îµ¥ ³Î¸® ºÐÆ÷Çϴ ¼¼Æ÷. °áÇÕÁ¶Á÷°ú Á¡¸·Á¶Á÷ ³»¿¡ Àִ ȣ¿°±â¼º »ö¼Ò·Î ÀÌ¿°»ö¼º(metachromasia)À» ³ªÅ¸³»´Â °ú¸³À» °¡Áø ¹æÃßÇüÀÇ ¼¼Æ÷¿¡ ÀÛÀº µÕ±Ù ÇÙÀ» °¡Áø´Ù. ºñ¸¸¼¼Æ÷ÀǠǥ¸é¿¡´Â IgE¿¡ ´ëÇÑ ¼ö¿ëü°¡ Á¸ÀçÇϸç, ¼ö¿ëü¿¡ °áÇÕÇÑ IgE ºÐÀڵ鳢¸® ´Ù°¡ÀÇ Ç׿ø¿¡ ÀÇÇØ ¼­·Î ¿¬°áµÇ¸é ºñ¸¸¼¼Æ÷ °ú¸³Å»Ãâ ¹ÝÀÀÀÌ ÀϾ, È÷½ºÅ¸¹Î, ¼¼·ÎÅä´Ñ, ÇìÆÄ¸° µîÀÇ È­ÇÐÀü´Þ ¹°ÁúÀÌ ¹æÃâµÇ¾î, Áï½ÃÇü ¾Ë·¹¸£±â ¹ÝÀÀ µîÀÇ Áõ»óÀ» ÀÏÀ¸Å²´Ù. ÇǺÎ, À帷, Ç÷°ü ÁÖÀ§, Á¡¸· ÁÖº¯¿¡ ÀÖ´Ù.
¿µ¹® cell ÇÑ±Û ¼¼Æ÷
¼³¸í   
  »ý¸íü¸¦ ÀÌ·ç´Â ±¸Á¶Àû, ±â´ÉÀû ´ÜÀ§.
  
  ÇÙÀÇ À¯¹«¿¡ µû¶ó¼­ À¯ÇÙ¼¼Æ÷¿Í ¹«ÇÙ¼¼Æ÷·Î ³ª´­ ¼ö°¡ ÀÖ´Ù. ¹«ÇÙ¼¼Æ÷¶õ ÇÙÀÌ ¾ø´Â ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. ÇÙÀ̶õ À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ ¿°»öü¸¦ º¸°üÇϴ °÷Àε¥ ¹«ÇÙ¼¼Æ÷¿¡¼­´Â ¿°»öü°¡ ¼¼Æ÷¼Ó¿¡ ±×³É ³ëÃâµÇ¾î ÀÖ´Ù. ´ë°³ ¼¼Æ÷ ÇϳªÇϳª°¡ µ¶¸³µÈ »ý¸íüÀÇ ¿ªÇÒÀ» Çϴ ´Ü¼¼Æ÷»ý¹°·Î¼­ ¿ÜºÎȯ°æÀ¸·ÎºÎÅÍ ÀÚ½ÅÀ» º¸È£ÇÒ ¼ö Àִ °ß°íÇÑ ¼¼Æ÷º®À» °¡Áö°í ÀÖ´Ù. À¯ÇÙ¼¼Æ÷¶õ ÇÙÀ» °¡Áö°í À־ À¯ÀüÁ¤º¸°¡ Àִ ¿°»öü°¡ ¼¼Æ÷ÀÇ ´Ù¸¥ ºÎºÐ°ú ±¸ºÐµÇ¾î ÇÙ¼Ó¿¡ µé¾îÀÖ´Ù. ¼¼Æ÷¼Ó¿¡¼­ ÇÙ¿ÜÀÇ ºÎºÐ(À̸¦ ¼¼Æ÷ÁúÀ̶ó ÇÑ´Ù)¿¡´Â ¿©·¯ °¡Áö ¼¼Æ÷ÀÇ ¼Ò±â°üÀÌ À־ ¼¼Æ÷ÀÇ ´Ù¾çÇÑ ±â´ÉÀ» ºÐ´ãÇÑ´Ù.
  
  ¢ÂÀ¯ÇÙ¼¼Æ÷ÀÇ ±âº» ±¸Á¶
  
  1.¼¼Æ÷¸·-¼¼Æ÷¸¦ µÑ·¯½Î¼­ ÁÖÀ§È¯°æ°ú ºÐ¸®ÇÏ¿© ¼¼Æ÷ÀÇ ³»È¯°æÀ» À¯ÁöÇÑ´Ù.
  
  2.ÇüÁú³»¼¼¸Á(endoplasmic reticulum)-´ÜÀ§¸·À¸·Î µÑ·¯½×¿© Àִ ºÒ±ÔÄ¢ÇÑ ¸Á»ó±¸Á¶ÀÌ´Ù. ÀÌ ¸Á»ó±¸Á¶ÀÇ ³»ºÎ¸¦ ¼Ò°­, ¼ÒÁ¶¶ó°í ºÎ¸¥´Ù. ¿©±â¿¡´Â Ç¥¸éÀÌ ¸Å²öÇÑ ¹«°ú¸³ÇüÁú³»¼¼¸Á°ú Ç¥¸éÀÌ ºÒ±ÔÄ¢ÇÑ °ú¸³ÇüÁú³»¼¼¸ÁÀÇ µÎ °¡Áö°¡ ÀÖ´Ù. °ú¸³ÇüÁú³»¼¼¸ÁÀÇ °æ¿ì´Â Ç¥¸é¿¡ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¸®º¸¼ØÀ̶ó´Â °ÍÀÌ ºÎÂøµÇ¾î ÀÖ´Ù. À̰÷Àº ÁַΠ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ Àå¼ÒÀÌ´Ù. ¹«°ú¸³ÇüÁú³»¼¼¸ÁÀº Ç¥¸é¿¡ ¸®º¸¼ØÀÌ ºÎÂøµÇ¾î ÀÖÁö ¾ÊÀº °ÍÀ» ¸»Çϸç, À̰÷¿¡¼­´Â ÁÖ·Î ÇØµ¶ÀÛ¿ë, ±Û¸®ÄÚ°ÕÀÇ ÇÕ¼º, ½ºÅ×·ÎÀ̵åÈ£¸£¸óÀÇ ÇÕ¼º µîÀÌ ÀϾ´Ù.
  
  3.¸®º¸¼Ø-´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¿ªÇÒÀ» Çϴ °÷ÀÌ´Ù.À̰ÍÀº ¼¼Æ÷Áú¿¡ Á¸ÀçÇϴ ÀÚÀ¯¸®º¸¼Ø°ú °ú¸³ÇüÁú³»¼¼¸Á¿¡ ºÎÂøÀÌ µÇ¾î Á¸ÀçÇϴ ºÎÂø¸®º¸¼ØÀÇ µÎ °¡Áö·Î ³ª´«´Ù. ÀÚÀ¯¸®º¸¼ØÀº ÁַΠ¼¼Æ÷³»¿¡¼­ ÇÊ¿äÇÑ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» Ç졒ʼÎÂø¸®º¸¼ØÀº ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  4.°ñÁöÀåÄ¡(Golgi apparatus)-ÇÙÁÖÀ§¿¡ ºÐÆ÷Çϴ ³³ÀÛÇØÁø ÁָӴϸð¾çÀÇ °ÍÀÌ ÁßøµÇ¾î Çü¼ºµÈ ÃþÆÇ ¸ð¾çÀÇ ±¸Á¶¹°·Î °ú¸³ÇüÁú³»¼¼¸Á¿¡¼­ »ý¼ºµÇ¾î ¿ÜºÎ·Î ºÐºñµÉ ´Ü¹éÁúÀ» ¸ð¾Æ¼­ ³óÃà, Æ÷ÀåÇÏ¿© °ú¸³À» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  5.»ç¸³Ã¼(mitochondria)-±¸Çü, ³­ÇüÀÇ ±ä ¸·´ë±â ¸ð¾çÀ¸·Î Å©±â°¡ ´Ù¾çÇÑ ±¸Á¶¹°. »ý¹°Ã¼ÀÇ ¿¡³ÊÁö ÀúÀå¹°ÁúÀΠATP¸¦ »ý»êÇϴ ¿ªÇÒÀ» ÇÑ´Ù. ¶Ç ¼¼Æ÷¿Í ´Ù¸¥ ÀڽŸ¸ÀÇ À¯ÀüÁ¤º¸¸¦ °¡Áø DNA, RNA¸¦ °¡Áö°í ÀÖ´Ù. ¸ð¾ç, Å©±â°¡ ¼¼±Õ°ú ºñ½ÁÇϸç ÀÚüÁõ½Ä¼º µî µ¶¸³µÈ »ý¸íü·Î¼­ ÇÊ¿äÇÑ ¿ä°ÇÀ» °®Ãß°í À־ ¼¼Æ÷¿Í °ø»ý°ü°è¸¦ °¡Áø µ¶¸³µÈ ¼¼Æ÷·Î »ý°¢Çϰí ÀÖ´Ù.
  
  6.¿ëÇØ¼Òü(lysosome)-ÀÛÀº ±¸ÇüÀÇ ¼Òü·Î ¿©·¯ °¡Áö ºÐÇØÈ¿¼Ò¸¦ °¡Áø´Ù. ¼¼Æ÷¿Ü°è¿¡¼­ µé¾î¿Â ¹°Áú°ú °áÇÕÇÏ¿© ±× ¹°ÁúµéÀ» ¿ëÇØÇϴ ¿ªÇÒÀ» Çϰí, ¿À·¡µÈ ¼¼Æ÷¼Ò±â°üµéÀ» Á¦°ÅÇϴ ¿ªÇÒµµ ÇÑ´Ù.
  
  7.¼¼Æ÷ÇÙ(nucleus)-±¸Çü, ³­ÇüÀ¸·Î ¼¼Æ÷ÀÇ Á߽ɿ¡ À§Ä¡ÇÑ´Ù. ÇÙ³»¿¡´Â À¯ÀüÁ¤º¸°¡ Àִ ¹°ÁúÀΠ¿°»öü°¡ Á¸ÀçÇÑ´Ù.
  
  8.Á߽ɼÒü(centrosome)-ÇÙÁÖÀ§¿¡ Á¸ÀçÇϸ鼭 ÇÙÀÇ ºÐ¿­½Ã¿¡ ¾çÂÊÀÇ ¿°»öü¸¦ ´ç±â´Â ÀÛÀº ¼¶À¯¸¦ ¸¸µå´Â ¿ªÇÒÀ» Çϴ °÷.
  
  ¼¼Æ÷
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • host-range mutant
    ¼÷ÁÖ¹üÀ§µ¹¿¬º¯ÀÌÁÖ
  • intermediate host
    Áß°£¼÷ÁÖ
  • primary host
    Á¾¼÷ÁÖ
  • paratenic host
    ¿¬Àå¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • susceptible host
    °¨¼ö¼º¼÷ÁÖ
  • unnatural host
    ºñÈ£Àû¼÷ÁÖ
  • antihemophilic factor
    Ç×Ç÷¿ìº´ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰ÀÎÀÚ
  • antipellagra factor
    Çׯç¶ó±×¶óÀÎÀÚ
  • antiphagocytic factor
    Çׯ÷½ÄÀÎÀÚ, Ç׎½ÄÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • antirachitic factor
    Ç×±¸·çº´ÀÎÀÚ
  • antiscorbutic factor
    Ç×±«Ç÷º´ÀÎÀÚ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • sickle cell anemia
    ³´ÀûÇ÷±¸ºóÇ÷
  • cell
    ¼¼Æ÷
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • acinar cell
    »ù²Ê¸®¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
  • host range mutation
    ¼÷ÁÖ¹üÀ§º¯ÀÌ, ¼÷ÁÖ¿ªº¯ÀÌ
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • host-parasite relationship
    ¼÷ÁÖ±â»ýü»óÈ£°ü°è
  • host-parasite specificity
    ¼÷ÁÖ±â»ýÃæÆ¯À̼º
  • host-range mutant
    ¼÷ÁÖ¹üÀ§º¯ÀÌÁÖ, ¼÷ÁÖ¿ªµ¹¿¬º¯ÀÌü
  • intermediate host
    Áß°£¼÷ÁÖ
  • natural host
    ÀÚ¿¬¼÷ÁÖ
  • paratenic host
    ¿¬Àå¼÷ÁÖ
  • primary host
    (¢¡definitive host) ÃÖÁ¾¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • B cell growth factor (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • B cell stimulating factor (BSF)
    B¼¼Æ÷ ÀÚ±ØÀÎÀÚ
  • T cell activating factor
    T¼¼Æ÷Ȱ¼ºÀÎÀÚ
  • T cell factor (TCF)
    T¼¼Æ÷
  • T cell growth factor (TCGF, IL-2)
    T¼¼Æ÷ Áõ½ÄÀÎÀÚ
  • T cell replacing factor
    T¼¼Æ÷ ´ëüÀÎÀÚ
  • T-cell growth factor
    T-¼¼Æ÷¼ºÀåÀÎÀÚ
  • growth factor, B cell (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • NK cell [=natural killer cell]
    ÀÚ¿¬»ì»ó¼¼Æ÷
  • alpha cell glucagon cell
    ¾ËÆÄ¼¼Æ÷ ±Û·çÄ«°ï¼¼Æ÷
  • quiescent cell, Q cell
    Á¤Áö¼¼Æ÷
  • AHF=£¾antihemophilic factor
    Ç×Ç÷¿ìÀÎÀÚ.
  • Castles extrinsic factor
    Ĺ½½¿ÜÀÎÀÚ.
  • Castles intrinsic factor
    Ĺ½½³»ÀÎÀÚ.
  • Christmas factor
    Å©¸®½º¸¶½º ÀÎÀÚ(ì×í­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • host attribute
    ¼÷ÁÖ¼Ó¼º.
  • host computer
    ÁÖ ÄÄÇ»ÅÍ
  • host controlled variation
    ¼÷ÁÖÀÇÁ¸(±ÔÁ¦)º¯ÀÌ.
  • host defense
    ¼÷ÁÖ¹æ¾î
  • host range
    ¼÷ÁÖ¹üÀ§, ¼÷ÁÖ¿ª
  • host range mutation
    ¼÷ÁÖ¿ªº¯ÀÌ
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • host-parasite relationship
    ¼÷ÁÖ-±â»ýü »óÈ£°ü°è
  • host-parasite relationship
    ¼÷ÁÖ±â»ýü°ü°è
  • host-parasite relationships
    ¼÷ÁÖ ±â»ýÃæ(»ó°ü) °ü°è
  • host-range mutant
    ¼÷ÁÖ¹üÀ§º¯ÀÌÁÖ
  • intermediate host
    Áß°£¼÷ÁÖ
  • mutant, host range
    ¼÷ÁÖ¿ª µ¹¿¬º¯ÀÌÁÖ
  • pneumonia,in immunocompromised host
    ¸é¿ª±â´ÉÀúÇϼ÷ÁÖÀÇ (Øóæ¹Ñ¦Òöî¸ù»âÖñ«¡­)
  • relation[ship], host-parasite
    ¼÷ÁÖ-±â»ýü »óÈ£°ü°è
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Striated muscle cell
    °¡·Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ⱦ¹®±Ù¼¼Æ÷
  • Sensory epithelial cell
    °¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢»óÇǼ¼Æ÷
  • Cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁú³»ºÐºñ¼¼Æ÷
  • Nodal cell
    °áÀý¼¼Æ÷
    [¿¾ ¿ë¾î] °áÀý¼¼Æ÷
  • Granule cell
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³¼¼Æ÷
  • Granular lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Myoepithelial cell
    ±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±Ù»óÇǼ¼Æ÷
  • Myoid cell layer
    ±ÙÀ°¼¶À¯¸ð¼¼Æ÷Ãþ
    [¿¾ ¿ë¾î] ±Ù¼¶À¯¾Æ¼¼Æ÷Ãþ
  • Satellite cell of skeletal muscle
    ±ÙÀ°À§¼º¼¼Æ÷
    [¿¾ ¿ë¾î] ±ÙÀ§¼º¼¼Æ÷
  • Sebaceous cell
    ±â¸§»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁö¼¼Æ÷
  • Centroacinar cell
    ²Ê¸®Á߽ɼ¼Æ÷
    [¿¾ ¿ë¾î] ¼±Æ÷Á߽ɼ¼Æ÷
  • Thecal cell
    ³­Æ÷¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ³­Æ÷¸·¼¼Æ÷
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • first intermediate host
    Á¦ÀÏÁß°£¼÷ÁÖ
  • host
    ¼÷ÁÖ
  • host parasite relationship
    ¼÷ÁÖ±â»ýÃæ°ü°è
  • host preference
    ¼÷ÁÖ¼±È£
  • host range
    ¼÷ÁÖ¹üÀ§
  • host selection
    ¼÷ÁÖ¼±ÅÃ
  • host specificity
    ¼÷ÁÖÆ¯À̼º
  • host susceptibility
    ¼÷ÁÖ°¨¼ö¼º
  • host-parasite specificity
    ¼÷ÁÖ±â»ýÃæÆ¯À̼º
  • intermediate host
    Áß°£¼÷ÁÖ
  • natural host
    ÀÚ¿¬°¨¿°¼÷ÁÖ
  • principal host
    ÁÖ¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • second intermediate host
    Á¦ÀÌÁß°£¼÷ÁÖ
  • susceptible host
    °¨¼ö¼º¼÷ÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • APUD cell
    APUD ¼¼Æ÷(á¬øà)
  • argentaffin cell
    ¾Æ¸£Á¨Å¸ÇÉ ¼¼Æ÷(á¬øà)
  • autosynthetic cell
    ÀÚ°¡ÇÕ¼º¼¼Æ÷ (í»Ê«ùêà÷á¬øà)
  • barrier layer cell
    À庮Ãþ(î¡Ûúöµ) ¼¼Æ÷(á¬øà)
  • B cell
    B ¼¼Æ÷(á¬øà)
  • cell adhesion
    ¼¼Æ÷ºÎÂø(á¬øàÜõó·)
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
  • cell fractionation
    ¼¼Æ÷ºÐȹȭ(á¬øàÝÂüñûù)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • blood cell
    Ç÷±¸
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò, °ÇÀüÁö
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷
  • daughter cell
    µþ¼¼Æ÷, ³¶¼¼Æ÷
  • dendrite cell
    ³ª¹«°¡Áö¼¼Æ÷, ¼ö»ó¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diffuse large cell lymphoma
    ¹Ì¸¸¼º Å«¼¼Æ÷ÀÓÆÄÁ¾
  • ependymal cell
    ³ú½Ç¸· ¼¼Æ÷, »óÀǼ¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • foam cell
    Æ÷¸» ¼¼Æ÷
  • follicular cell
    ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
  • germ cell
    »ý½Ä¼¼Æ÷, ¹è¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PAF paroxysmal atrial fibrillation; peroxisomal assembly factor; phosphodiesterase-activating factor; pl...
TF free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ...
HDF host defense factor; human diploid fibroblast
IHF Industrial Health Foundation; integration host factor; International Hospital Foundation
ACC accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
cGVHD Chronic graft-vs.-host disease
GVHD Graft Versus Host Disease
GvHR Graft v Host Reaction
GvH Graft versus Host
GVH Graft versus host reaction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antiangiogenesis factor
    Ç×Ç÷°ü»ý¼º ÀÎÀÚ
    Harvard ´ëÇп¡¼­ ¿¬±¸µÈ °ÍÀε¥ ¿¬°ñ¿¡´Â ¸ð¼¼Ç÷°üÀÌ Ä§ÅõµÇÁö ¾Ê´Â Çö»óÀ» °üÂûÇÏ°í ¾Ï Á¶Á÷¿¡ ¿¬°ñÁ¶Á÷¿¡¼­ À¯·¡µÈ antiangiogenesis factor¶ó´Â °ÍÀ» »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ ¼èÅ𸦠ÃÊ·¡ÇÏ¿´´Ù.
  • antihemophilic factor
    Ç×Ç÷¿ìº´ ÀÎÀÚ
  • antineuritic factor
    Ç׽Ű濰 ÀÎÀÚ
  • antistiffness factor
    Ç×°­Á÷ ÀÎÀÚ
  • atrial natriuretic factor
    ½É¹æ¼º ³ªÆ®·ý ÀÌ´¢ ÀÎÀÚ
  • attenuation factor
    °¨¾à ¿ä¼Ò, °¨¼è ¿äÀÎ
  • back scatter factor
    ÈÄ¹æ »ê¶õ °è¼ö
  • beam direction factor
    ¼±¼Ó ¹æÇâ ÀÎÀÚ
    ÀüÀÚÆÄ ¹æ»ç¼± ¶Ç´Â ÀÔÀÚ°¡ °°Àº ¹æÇâÀ¸·Î ¹æÃâÇÏ ´Â ¼Ó ¶Ç´Â ¼±ÀÇ ¹æÇâÀÇ ÀÎÀÚ.
  • behavioral factor
    Çൿ ¿äÀÎ
  • biological factor
    »ý¹°ÇÐÀû ¿äÀÎ
  • biotic factor
    »ý¹° ÀÎÀÚ
  • blood factor
    Ç÷¾× ÀÎÀÚ
  • bone factor
    °ñ ÀÎÀÚ
    Ȱ¼ºÀ̳ª ÀÚÁï¿¡ ´ëÇÑ Ä¡Á¶°ñÀÇ »ó´ë ¹ÝÀÀ.
  • Castle factor
    ij½½ ÀÎÀÚ
    ½ÄǰÀ̳ª À§¾× ¼Ó¿¡ ÀÖ´Â Ç׺óÇ÷ ÀÎÀÚ. À̰ÍÀÌ °áÇÌµÇ¸é ¾Ç¼º ºóÇ÷ÀÌ µÈ´Ù. À§¾×¿¡ ÇÔÀ¯µÈ ij½½³» ÀÎÀÚ¿Í ½Äǰ¿¡ ÇÔÀ¯µÈ ij½½¿Ü ÀÎÀÚ°¡ ÀÖ´Ù. ³»ÀÎÀÚ°¡ °áÇÌµÇ¸é ½Äǰ ³»ÀÇ ¿ÜÀÎÀÚ°¡ Èí¼öµÇÁö ¾Ê°í ¾Ç¼º ºóÇ÷ÀÌ ÀϾ´Ù. À§ ¾Ï µîÀ¸·Î À§¸¦ ÀüºÎ Àß¶ó¹ö¸®¸é ºóÇ÷ÀÌ ÀϾ´Â °ÍÀº ³»ÀÎÀÚ°¡ ¾ø¾îÁö±â ¶§¹®ÀÌ´Ù. ³»ÀÎÀÚ´Â ºÐÀÚ·® ¾à 10¸¸ÀÎ ´Ü¹éÁú·Î À§º®ÀÇ ¹æ ¼¼Æ÷¿¡¼­ ºÐºñµÈ´Ù. ¿ÜÀÎÀڷμ­´Â ºñŸ¹Î D°¡ °ü°èÇÑ´Ù. 1927³â ¹Ì±¹ÀÇ W.B. ij½½ÀÌ Ã³À½À¸·Î ÀÌ·¯ÇÑ ±¸Á¶¸¦ Á¦Ã¢ÇÏ¿´´Ù.
  • Castles extrinsic factor
    ij½½ ¿ÜÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
host restriction-modification A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it.
(09 Oct 1997)
host-vector system A combination of a bacterial host cell (i.e. A specific strain) and a virus vector (i.e. A particular bacteriophage strain) which work well together for DNA cloning.
(09 Oct 1997)
host versus graft reaction The normal lymphocyte mediated reactions of a host against allogeneic or xenogeneic cells acquired as a graft or otherwise, which lead to damage or/and destruction of the grafted cells. The opposite of graft-versus-host reaction. The common basis of graft rejection.
(18 Nov 1997)
host vs graft reaction The immune responses of a host to a graft. A specific response is graft rejection.
(12 Dec 1998)
dead-end host A host from which infectious agents are not transmitted to other susceptible host's.
(05 Mar 2000)
definitive host <epidemiology> The host in which a parasite reproduces sexually.
(05 Dec 1998)
disease, graft-versus-host A reaction of donated bone marrow against a patient's own tissue. Also called GVHD.
(12 Dec 1998)
immunocompromised host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
(12 Dec 1998)
intermediate host <epidemiology> See vector.
(05 Dec 1998)
transport host An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's.
Synonym: transport host.
(05 Mar 2000)
type host <zoology> The host species with which the name-bearing type of a nominal species or subspecies was associated.
(09 Jan 1998)
final host <epidemiology> The host in which a parasite reproduces sexually.
(05 Dec 1998)
B-cell differentiating factor <cytokine> A soluble cytokine factor produced by activated T-lymphocytes that promotes antibody production by causing proliferation and differentiation of B-cells.
Interleukin-4 induces the expression of class II major histocompatibility complex and fc receptors on B-cells. It also acts on T-lymphocytes, mast cell lines, and several other haematopoietic lineage cells including granulocyte, megakaryocyte, and erythroid precursors, as well as macrophages.
Acronym: IL-4
(12 Dec 1998)
B-cell stimulatory factor 2 <cytokine> A cytokine that stimulates the growth and differentiation of human B-cells and is also a growth factor for hybridomas and plasmacytomas.
It is produced by many different cells including T-cells, monocytes, and fibroblasts. A single chain 25 kD cytokine originally described as a pre B-cell growth factor, now known to have effects on a number of other cells including T-cells which are also stimulated to proliferate.
An inducer of acute phase proteins and a colony-stimulating factor acting on mouse bone marrow.
Acronym: IL-6
(12 Dec 1998)
natural killer cell stimulating factor <cytokine> A 75 kD heterodimeric cytokine composed of disulfide-bonded 40 kD and 35 kD subunits that was originally identified by its ability to induce cytotoxic effector cells in synergy with less than optimal concentrations of interleukin-2.
It is released by macrophages in response to infection and promotes the activation of cell-mediated immunity. Specifically, IL-12 triggers the maturation of Thl CD4 cells, specific cytotoxic T-lymphocyte responses and an increase in the activity of NK cells and consequently, it is the initiator of cell-mediated immunity.
It enhances the lytic activity of NK cells, induces interferon production, stimulates the proliferation of activated T-cells and NK cells. Is secreted by human B lymphoblastoid cells (NC 37). May play a role in controlling immunoglobulin isotype selection as it also inhibits IgE synthesis (even in the presence of anti-IFN monoclonal antibody) and as a growth factor for activated CD4+ and CD8+ T-cells independently of interleukin-2, and for CD56+ NK cells but not resting peripheral blood mononuclear cells or resting or activated tonsillar B-cells.
It is likely that interleukin 12 has a major role in protective immunity against viruses and is under study as an immunotherapy in HIV infection.
Formerly referred to as cytotoxic lymphocyte maturation factor.
Acronym: IL-12
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
  • pp factor
    Ç× Æç¶ó±×¶ó ÀÎÀÚ(Æç¶ó±×¶ó ¿¹¹æ¿¡ ¾²´Â ´ÏÄÚÆ¾»ê,´ÏÄÚÆ¾»ê¸¶À̵å)
  • prime factor
    ¼ÒÀμö
  • releasing factor
    È£¸£¸ó ¹æÃâÀÎÀÚ
  • rheumatoid factor
    ·ù¸ÓƼÁòÀÎÀÚ(¸¸¼º °üÀý ·ù¸ÓƼÁò ȯÀÚÀÇ ÀÚ±â Ç×ü)
  • cell
    ¼¼Æ÷
  • HeLa cell
    Èú·¯ ¼¼Æ÷(¿¬±¸¿ëÀ¸·Î ¹è¾çµÇ°í ÀÖ´Â ¾Ï¼¼Æ÷ÀÇ ÀÏÁ¾)
  • blood cell
    Ç÷±¸
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á